Baxter International (BAX) will acquire Claris Injectables for $625 million. Claris will sell Baxter its injectable generic medicines such as drugs for anesthesia and analgesics. This year Claris is expected to report revenue of $100 million. Revenue for Claris has increased by a double-digit percentage annually over the last several years as the company launched new products. The deal is expected to immediately add to Baxter's earnings. It is set to close in the second half of next year. Claris is a unit of Claris Lifesciences.
More from Video
How quickly do we find support, is what we'll want to know now, as the correction is occurring while economic optimism builds.
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.